Results 171 to 180 of about 29,549 (204)

Sensitizing ROS1 Fusion Positive [PDF]

, 2020
openaire   +1 more source

Toxicity profiles of ROS1 tyrosine kinase inhibitors in advanced non-small cell lung cancer: a systematic review and proportional meta-analysis. [PDF]

Front Pharmacol
Jiang BX, Zeng JW, Yan JJ, Zhao LY.
europepmc   +1 more source

ROS1 Rearrangement Testing Method [PDF]

, 2020
openaire   +1 more source

Postoperative incision metastasis of lung cancer: A case report. [PDF]

J Int Med Res
Zhao S, Wang J, Xiang M, Liu Q.
europepmc   +1 more source

De Novo EGFR -ALK and EGFR -ROS1 Co-Mutations in NSCLC: Clinical Characteristics, Molecular Profiling, and Treatment Outcomes From a Retrospective Analysis. [PDF]

Cancer Med
Shen L, Deng H, Liao W, Gu Q, Ma L, Jiang Q, Liu K.   +6 more
europepmc   +1 more source

Diagnostic and predictive molecular biomarkers in brain tumors across the lifespan: an age-stratified consensus statement. [PDF]

J Neurooncol
Mastronuzzi A, Franceschi E, D'Antonio F, Bennicelli E, Berzero G, Cella E, Filippi M, Lanzetta G, Marchioni E, Milanaccio C, Simonelli M, Bini P, Silvani A, Pace A.   +13 more
europepmc   +1 more source

Exploring the mutational spectrum of key kinase genes PIK3CA, BRAF, EGFR, ALK and ROS1 in oral squamous cell carcinoma. [PDF]

BMC Cancer
Nawab F, Naeem W, Fatima S, Ali A, Khalil AT, Mehmood A, Fazeel M, Ahmad H, Alorini M, Khan M, Khan IA, Irfan M, Khurram SA.   +12 more
europepmc   +1 more source

Cabozantinib overcomes ROS1 L2086F NSCLC resistance to lorlatinib: A case report. [PDF]

Medicine (Baltimore)
Liu X, Chen Q, Shao L, Luo P, An JH.
europepmc   +1 more source

Exposure-Response Analysis of Repotrectinib to Support the Dose Recommendation for Patients With ROS1-Positive NSCLC or NTRK-Positive Solid Tumors. [PDF]

CPT Pharmacometrics Syst Pharmacol
Du S, Hu Z, Shen J, Zhu L, Roy A, Lam J, Lu M, Kondic A, Hamuro L.   +8 more
europepmc   +1 more source